BPC-157 + TB-500 Recovery Stack

Published BPC-157 animal studies have used doses of 10 µg/kg to 10 mg/kg administered intraperitoneally or subcutaneously. TB-500 (Thymosin Beta-4) animal studies have used doses of 150 µg/kg to 6 mg/kg via subcutaneous or intramuscular administration.

All figures are drawn from published preclinical research and are provided for research reference only. They do not constitute dosing recommendations for human use.

Recovery research protocols in the literature typically use a 12–16 week observation period for musculoskeletal injury models: 0–4 weeks (acute injury + immediate treatment), 4–8 weeks (proliferative repair phase), 8–16 weeks (remodeling and functional recovery assessment). BPC-157 and TB-500 are often co-administered from week 0 due to their complementary mechanisms — BPC-157 for vascular restoration, TB-500 for cell migration and actin remodeling.

Researchers monitoring BPC-157/TB-500 recovery protocols have measured: tendon tensile strength (mechanical testing); collagen fibre organisation (polarised light microscopy of Sirius Red-stained sections); VEGF expression (IHC or ELISA); new vessel density (CD31/PECAM-1 staining); muscle satellite cell activation (Pax7 immunofluorescence); and functional recovery scores (e.g., Sciatic Functional Index in nerve models). Blood panels in rodent studies include: CRP (inflammatory marker), complete blood count, and liver enzymes (AST/ALT).

Both peptides have favourable preclinical safety profiles with no significant organ toxicity reported at research doses. BPC-157 is derived from gastric protective protein and has been studied for gastroprotective safety. TB-500 (Tβ4) is endogenous and present in all nucleated cells; exogenous administration in animal models has not produced adverse organ effects. No significant drug-drug interactions have been identified in preclinical literature.

Protocol Overview

This protocol outlines the research parameters for combined BPC-157 + TB-500 musculoskeletal repair investigations, drawn from published preclinical literature. It is intended as a reference for researchers designing recovery peptide studies.

Research goal: Musculoskeletal recovery — tendon, ligament, muscle repair Primary peptides: BPC-157 + TB-500 (Thymosin Beta-4) Duration: 12 weeks Model systems: Rodent tendon transection, crush injury, ACL repair, Achilles repair models

Scientific Rationale for the Stack

BPC-157 and TB-500 are the most studied recovery peptides in the literature, and they act through distinct, complementary mechanisms that make them logical co-administration candidates:

• BPC-157 targets the vascular layer: VEGF upregulation drives new capillary formation into the injury site, restoring oxygen and nutrient delivery. FAK-paxillin signalling promotes fibroblast migration into the damaged matrix.
• TB-500 targets the cellular layer: G-actin sequestration enables rapid cytoskeletal remodeling for cell migration; ILK-Akt-ERK signalling promotes satellite cell activation in muscle and fibroblast survival in tendon/ligament.

Together they address two complementary phases of tissue repair: vascular restoration (BPC-157) and cellular infiltration and matrix remodeling (TB-500).

Key Endpoints

• Tendon tensile strength (mechanical testing at 4, 8, 12 weeks)
• Collagen fibre organisation (Sirius Red, polarised light microscopy)
• VEGF and CD31 (angiogenesis markers)
• Pax7 staining (muscle satellite cell activation)
• Sciatic Functional Index (for nerve recovery co-models)

Referenced Research

• [Sikiric 2018 — BPC-157 Muscle Healing](/research/sikiric-2018-bpc-157-muscle-healing)
• Goldstein & Kleinman 2015 — Thymosin Beta-4
• BPC-157 Monograph
• TB-500 Monograph

Research Use Only · Not for human consumption · Consult a qualified researcher or physician before any protocol.